Impact of Phase II Data on Bapineuzumab Perceptions
A Panel Discussion among Eleven Neurologists
Panel Intelligence, LLC
Deliverable: Transcript with key findings
Study Description and Objectives
Panel Intelligence engaged a set of 11 neurologists to determine the potential for bapineuzumab based on recently released phase 2 data via an online panel discussion. Secondary objectives of this study included the following:
· To evaluate the clinical effectiveness and safety of bapineuzumab based on phase 2 data
· To assess the validity of the study design and end points of the clinical trial
· To evaluate the significance of the trial outcomes among ApoE4 carriers and non-carriers
· To gauge the future potential and limitations of bapineuzumab in clinical practice
Companies and Products Mentioned in This Report
|
Company |
Ticker Symbol |
Product |
|
Elan |
ELN |
bapineuzumab |
|
Wyeth |
WYE |
bapineuzumab |
Inclusion Criteria and Panel Details
|
Inclusion Criteria |
§ US-based board-certified neurologist § Practicing at an academic medical center § Currently treating patients with Alzheimer’s disease § Published expert in Alzheimer’s and runs clinical trials in Alzheimer’s |
|
Discussion Dates |
August 6th, 2008 through August 15th, 2008 |
Panelists' Institutions
|
Hospital Affiliation |
State |
|
Beth Israel Deaconess Medical Center |
MA |
|
Boston University School of Medicine |
MA |
|
Cleveland Clinic - Florida |
FL |
|
Duke University Medical Center |
NC |
|
Emory University |
GA |
|
Henry Ford Hospital |
MI |
|
Neurology Clinical Research |
FL |
|
Newton Memorial Hospital |
NJ |
|
North Shore Long Island Jewish |
NY |
|
Rose Medical Center |
CO |
|
University of California, San Francisco |
CA |
Print Abstract
For additional information on this study or to purchase, please call:
|
Discussion
Neuro |